Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) traded down 6.7% during mid-day trading on Tuesday ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have been assigned an average recommendation of “Buy” ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS). IPWSO hopes the US FDA approval is the ...

Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, ...

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) today and set a price target of ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $70 and keeps a Buy rating on the shares after the ...

We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look ...

US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome: Redwood City, California Saturday, March 29, 2025, 18:00 Hrs [IST] Soleno Therapeuti ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...